At a glance
ClinicalIndex Comparison RecordN/ACompleted· 200 enrolled
Drug / intervention
Valproic Acidgenetic
Likely dose
Valproic Acid 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
SCN2A, rs2304016 Polymorphisms Are Associated With Response to Valproic Acid in Paediatric Epilepsy Patients (Pakistan)
In Brief
An observational study evaluating Valproic Acid for Epilepsy. Completed, enrolled 200 participants across 1 site.
Detailed Summary
The goal of this Observational study was to identify the effect of SCN2A gene polymorphism in the Paediatric epileptic Pakistani population. The main question it aims to answer is: to evaluate the effect of this genetic polymorphism on the clinical efficacy of Valproic acid Participants were prescribed Valproic acid after diagnosis of epilepsy.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesPakistan
Collaborators--
Timeline
N/ACompletedFinished
202420252026
Enrollment StartDec 2023
Primary CompletionJul 2024
Study CompletionAug 2024
First PostedNov 2024
TodayJul 2026
First PostedNov 5, 2024
Enrollment StartDec 1, 2023
Primary CompletionJul 31, 2024
Study CompletionAug 31, 2024
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 1.7 years ago
Interventions
Valproic Acidgenetic
syrup/ tablet EPIVAL (250mg